Diligent Announces Enterprise Risk Management Dashboard Powered by Moody’s Proprietary Data, Providing a Comprehensive View of External Risk
Diligent, a leading GRC SaaS company, today announced a first-of-its-kind Enterprise Risk Management (ERM) dashboard powered by industry-leading market data from Moody’s (NYSE: MCO), the leading source of relevant insights on exponential risk. The dashboard will help Chief Risk Officers, Chief Financial Officers, general counsel and other risk professionals monitor critical risk factors, aggregate findings and present a clear and comprehensive report to the board to drive informed decisions and long-term success for the organization.
The ERM dashboard complements the recent launch of Board Reporting for ERM from Diligent, which provides organizations with a clear and consistent view of their internal risk posture. Together, leaders can gain a comprehensive understanding of both internal and external risk to drive decision making.
“As a board member, the ability to gain a clear picture of risks — from ESG or operational risks to supplier and competitor risks, market fluctuations, and financial health – is enormously useful,” said Patricia Galloway, Board Director at Stantec and Chairman of Pegasus Global Holding, Inc. “To me, the ability for practitioners to easily collect and collate risk data, and then present it in a way that tells a clear story of an organization’s external risk footprint, complemented by internal risk data, is what really sets this apart.”
“We’re thrilled to join forces with Moody’s to help organizations gain greater transparency into their risk identification and mitigation efforts against a complex and fluid risk landscape,” said Brian Stafford, President and CEO of Diligent. “The dashboard will make it easier for CFOs, GCs and risk professionals to pre-emptively identify risks lurking in the market and value chain, gain clearer visibility into potential exposure to operational and financial risks; and improve board and executive communication with clear and concise reporting.”
Leveraging powerful proprietary data from Moody's along with the ability to add valuable internal risk data aggregated from Diligent, the ERM dashboard provides:
- A holistic view of external risk with access to Moody's data including credit risk assessments, supplier performance risks scores, credit sentiment scores and country risk index.
- Data-driven decision-making to pre-emptively identify risk and enhance oversight, leveraging insights from Moody's comprehensive data sets.
- Effortless reporting to the C-suite and board, streamlining communication and delivering clear and concise insights to foster proactive risk management strategies.
“Navigating exponential risk in today’s dynamic business landscape is a key priority for today’s business leaders,” said David Platt, Chief Strategic Development Officer at Moody’s. “The ERM dashboard combines Moody’s vast and proprietary data estate with Diligent’s advanced technology to provide a comprehensive view of risks, empowering leaders to make informed decisions that help decode risk and unlock opportunity.”
Visit us here to learn more about the ERM dashboard with Moody’s.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
About Moody’s Corporation
In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of 15,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at www.moodys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515779465/en/
Contact information
MEDIA
Kelly Blum
Senior Director, Communications at Diligent
770.354.1693
Kblum@diligent.com
Chris Cashman
Corporate Communications
212.553.1461
chris.cashman@moodys.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom